

## DEPARTMENT OF HEALTH & HUMAN SERVICES

## PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:
Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

FOR EXPRESS MAIL
Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Teicohone: (301) 496-7163
Facsimils: (301) 402-7065

February 5, 2019

Re: Animal Welfare Assurance A3158-01 [OLAW Case 1E]

Judith A. Neubauer, Ph.D.
Associate Vice President for Research Regulatory Affairs
University of Medicine and Dentistry of New Jersey
New Jersey Medical Schools
65 Bergen Street
SSB 519, PO Box 1709
Newark, NJ 07101-1709

Dear Dr. Neubauer,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your January 23, 2019 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at Rutgers University. Your letter supplements the information in the initial phone report on November 28, 2018. According to the information provided, OLAW understands that on September 20, 2018, one dog had bloody diarrhea and another dog had vomiting and bloody diarrhea. A veterinarian examined the dogs and prescribed treatment. No bloody stool or vomiting was observed in either dog since the following day after treatment. Both dogs had been administered L-NAME (N-nitro-L-arginine methyl ester) at 30 mg/kg SC. It was noted that although L-NAME administration is approved in the protocol, it was approved for 10-20 mg/kg IV, not the route and dose at which it was administered. It was also noted that the protocol indicated that L-NAME is a pharmaceutical grade compound, but it is not. It is noted that this study was not supported by NIH funds.

Corrective and preventive actions included instructing the lab staff to read the lab's protocols and review dosing with CMR staff. Other institutions where L-NAME is used in dogs were to be contacted to see if these symptoms have been observed and at what formulation. New L-NAME was to be obtained and verified with CMR that the compound was made and stored properly. An amendment to clarify that L-NAME is not a pharmaceutical grade compound was to be submitted to this protocol. A pilot experiment was to be performed, in consultation with and in the presence of veterinary staff, to give the drug at a dose of 10 mg/kg IV and a similar IP dose to a single mouse and observe for 48 hours. If no adverse effects are noted, then the use [of] a lower dose IV in a single dog in consultation with veterinary staff.

The prompt consideration of this matter by Rutgers University was consistent with the philosophy of institutional self-regulation. Similarly, the actions taken to resolve the issues were appropriate. Although this activity was not PHS funded, the application of the standards of the PHS Policy across the animal care and use program reduces any potential appearance of a double standard. We appreciate being informed of this matter and find no cause for further action by this office.

Page 2 – Dr. Neubauer February 5, 2019 OLAW Case A3158-1E

Sincerely,

(b) (6)

Brent C. Morse, DVM Director Division of Compliance Oversight Office of Laboratory Animal Welfare

cc: IACUC Chair

Laszlo M. Szabo, Esq., Dir. Office of Regulatory Affairs Dr. Robert M. Gibbens, USDA, APHIS, AC



Office of Research Regulatory Affairs RWJMS, Research Tower Rutgers, The State University of New Jersey 675 Hoes Lane West, Room 115 Piscataway, NJ 08854 http://orra.rutgers.edu/

p. 732-235-6081 f. 732-235-5534

January 23, 2019

Brent Morse, DVM
Director, Division of Compliance Oversight
Office of Laboratory\_Animal Welfare
National Institutes of Health
Rockledge 1, Suite 360, MSC 7982
6705 Rockledge Drive
Bethesda, MD 20892-7982

Re:

Animal Welfare Assurance Number D16-00098 (A3158-01)

Dear Dr. Morse,

Rutgers University wishes to make a final report in which two dogs were administered an unapproved dose/route of an approved compound. The IACUC Manager first reported the incident via telephone call on November 28, 2018.

On September 20, 2018, one dog had bloody diarrhea and another dog had vomiting and bloody diarrhea. A veterinarian examined the dogs, KaoPectolin and a probiotic were administered to both, and no bloody stool or vomiting was observed in either dog since the following day after treatment. Staff interviewed reported no known changes in food or treats and that the dogs did not appear stressed and that they were unaware of anything else that may have led to the symptoms.

Both dogs had been exercised the previous day and administered L-NAME (N-nitro-L-arginine methyl ester) at 30 mg/kg SC. It was noted that although L-NAME administration is approved in the protocol, it was approved for 10-20 mg/kg IV, not the route and dose at which it was administered. It was also noted that the protocol indicated that L-NAME is a pharmaceutical grade compound, but it is not.

The following actions were taken in response to this incident:

- The lab staff were to be instructed to read the lab's protocols and review dosing with CMR staff.
- Other institutions where L-NAME is used in dogs were to be contacted to see if these symptoms have been observed and at what formulation.
- New L-NAME was to be obtained and verified with CMR that the compound was made and stored properly.
- An amendment to clarify that L-NAME is not a pharmaceutical grade compound was to be submitted to this protocol, as well as a mouse protocol that uses the same compound.
- A pilot experiment was to be performed, in consultation with and in the presence of veterinary staff, to
  give the drug at a dose of 10 mg/kg IV and similar IP dose to a single mouse and observe for 48
  hours. If no adverse effects are noted, then the use a lower dose IV in a single dog in consultation
  with veterinary staff.
- At its regular meeting on November 13, 2018, the IACUC reviewed and discussed this incident and unanimously voted to report this matter to OLAW. The IACUC also voted to accept the above noted corrective actions.

Please note that this study was not supported by NIH funds.

Please contact me with any questions.

Sincerely,


(b) (6)

Judith Neubauer, Ph.D. Institutional Official Associate Vice President for Research Regulatory Affairs

(b) (6) (b) (6)

(b) (6) (b) (6) (b) (6)

(b) (4)



## Initial Report of Noncompliance

Ву: / СП/1-

Date: 11/28/18	Time: (b) (6)
Name of Person reporting:  Telephone #:  Fax #:  Email:	(b) (6)
Name of Institution: Assurance number:  A3	tges U Newark
Did incident involve PHS fund Funding component: Was funding component conta	acted (if necessary):
What happened? I do in put	tocol. Also not correct dose.
Species involved: ( ) Personnel involved: ( ) Dates and times: ( ) Animal deaths:	
Projected plan and schedule for correction/prevention (if known):	

Projected submission to OLAW of final report from Institutional Official:

OFFICE USE ONLY
Case #\_\_\_\_